Neurocrine Biosciences (NBIX) Scheduled to Post Earnings on Thursday

Neurocrine Biosciences (NASDAQ:NBIX) is scheduled to be announcing its earnings results before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $7 EPS for the next fiscal year.

Neurocrine Biosciences Stock Performance

Shares of Neurocrine Biosciences stock opened at $141.18 on Wednesday. Neurocrine Biosciences has a 52-week low of $99.98 and a 52-week high of $150.39. The stock has a market cap of $14.21 billion, a PE ratio of 38.89 and a beta of 0.37. The firm has a 50-day moving average of $139.25 and a 200-day moving average of $138.13.

Analyst Ratings Changes

NBIX has been the topic of a number of analyst reports. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday. HC Wainwright increased their target price on shares of Neurocrine Biosciences from $150.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Wedbush restated an “outperform” rating and set a $152.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday, May 29th. Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $154.00 to $164.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Finally, BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $129.00 to $138.00 and gave the stock a “market perform” rating in a research report on Thursday, May 2nd. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $154.08.

Insider Activity at Neurocrine Biosciences

In other news, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares of the company’s stock, valued at $4,421,486.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the transaction, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at approximately $4,421,486.72. The disclosure for this sale can be found here. Insiders sold a total of 80,709 shares of company stock valued at $11,009,150 in the last quarter. Insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.